Veto activity of activated bone marrow does not require perforin and Fas ligand

被引:18
作者
Chrobak, P
Gress, RE
机构
[1] NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA
[2] Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada
关键词
mouse; CD8(+) T lymphocyte; peripheral tolerance; bone marrow; veto cell; IL-2; clonal deletion; perforin/granzyme; Fas/Fas ligand;
D O I
10.1006/cimm.2001.1771
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Veto cells suppress generation of CD8(+) T cell immune responses in an antigen-specific manner, with specificity dictated by antigens on the veto cell surface. Activated bone marrow (ABM) veto cells belong to the NK cell type lineage and veto by clonally deleting antigen-specific precursor cytotoxic T cell lymphocyte (CTL), In vitro cytotoxicity of ABM depends largely on the perforin/granzyme and Fas/Fas ligand pathways. Utilizing perforin-deficient and functional Fas ligand-deficient gld mice as a source of ABM and functional Fas-deficient lpr mice as a source of precursor CTL, we demonstrate in this study that ABM cells utilize a perforin- and Fas-independent pathway to veto allogeneic cell-mediated cytotoxic responses. We also show that ABM cells mediate perforin- and Fas-independent veto activity even in an g-h clonal deletion assay. We conclude that ABM veto activity does not require the two primary pathways of cell-mediated death.
引用
收藏
页码:80 / 87
页数:8
相关论文
共 40 条
[1]   Immunoregulatory role of CD8α in the veto effect -: Transforming growth factor-β1 activation [J].
Asiedu, C ;
Meng, YR ;
Wang, W ;
Huang, Z ;
Contreras, JL ;
George, JF ;
Thomas, JM .
TRANSPLANTATION, 1999, 67 (03) :372-380
[2]  
AZUMA E, 1988, J IMMUNOL, V141, P2601
[3]   Modulation of life and death by the TNF receptor superfamily [J].
Baker, SJ ;
Reddy, EP .
ONCOGENE, 1998, 17 (25) :3261-3270
[4]  
Bhandoola A, 1994, Int Rev Immunol, V11, P231, DOI 10.3109/08830189409061729
[5]   THYMIC EPITHELIAL-CELLS .1. EXPRESSION OF STRONG SUPPRESSIVE (VETO) ACTIVITY IN MOUSE THYMIC EPITHELIAL-CELL CULTURES [J].
CLAESSON, MH ;
ROPKE, C .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1990, 32 (06) :595-600
[6]  
Déas O, 1998, J IMMUNOL, V161, P3375
[7]  
FINK PJ, 1984, J IMMUNOL, V133, P1775
[8]  
FINK PJ, 1988, ANNU REV IMMUNOL, V6, P115
[9]  
FINK PJ, 1984, J IMMUNOL, V133, P1769
[10]   The molecular mechanisms of veto mediated regulation of alloresponsiveness [J].
George, JF ;
Thomas, JM .
JOURNAL OF MOLECULAR MEDICINE-JMM, 1999, 77 (07) :519-526